USA - NASDAQ:ISRG - US46120E6023 - Common Stock
The current stock price of ISRG is 565.51 USD. In the past month the price increased by 30.12%. In the past year, price increased by 7.18%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.9 | 224.97B | ||
| BSX | BOSTON SCIENTIFIC CORP | 35.59 | 155.55B | ||
| SYK | STRYKER CORP | 28.35 | 142.76B | ||
| IDXX | IDEXX LABORATORIES INC | 55.63 | 56.12B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.51 | 50.56B | ||
| RMD | RESMED INC | 25.47 | 36.79B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.12 | 33.77B | ||
| PODD | INSULET CORP | 72.79 | 23.42B | ||
| DXCM | DEXCOM INC | 32.11 | 23.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.2 | 17.94B | ||
| HOLX | HOLOGIC INC | 17.39 | 16.52B |
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 15,638 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
INTUITIVE SURGICAL INC
1020 Kifer Road
Sunnyvale CALIFORNIA 94086 US
CEO: Gary S. Guthart
Employees: 15638
Phone: 14085232100
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 15,638 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
The current stock price of ISRG is 565.51 USD. The price decreased by -1.21% in the last trading session.
ISRG does not pay a dividend.
ISRG has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
INTUITIVE SURGICAL INC (ISRG) has a market capitalization of 202.72B USD. This makes ISRG a Mega Cap stock.
INTUITIVE SURGICAL INC (ISRG) will report earnings on 2026-01-21, after the market close.
The outstanding short interest for INTUITIVE SURGICAL INC (ISRG) is 2.07% of its float.
ChartMill assigns a technical rating of 8 / 10 to ISRG. When comparing the yearly performance of all stocks, ISRG is one of the better performing stocks in the market, outperforming 75.77% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to ISRG. ISRG scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months ISRG reported a non-GAAP Earnings per Share(EPS) of 8.61. The EPS increased by 28.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.58% | ||
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| Debt/Equity | 0 |
41 analysts have analysed ISRG and the average price target is 608.71 USD. This implies a price increase of 7.64% is expected in the next year compared to the current price of 565.51.
For the next year, analysts expect an EPS growth of 19.93% and a revenue growth 21.17% for ISRG